【摘要】 目的 探讨艾司西酞普兰治疗女性更年期抑郁症患者的疗效和安全性。方法 将45例女性更年期抑郁症患者按就诊顺序分为两组,研究组22例,口服艾司西酞普兰治疗,对照组23例,予以常规对症治疗,观察8周。治疗前后采用汉密顿抑郁量表评定抑郁症状,副反应量表评定不良反应。结果 治疗后两组患者汉密顿抑郁量表评分呈持续性下降,研究组治疗各时点均较对照组下降更显著(P<0.05);治疗8周末研究组总有效率为68.2%,对照组为34.8%,研究组显著高于对照组(x~2=6.14,P<0.05)。两组不良反应均较轻微,发生率比较差异无显著性(P>0.05)。结论 艾司西酞普兰治疗女性更年期抑郁症起效快,疗效显著,安全性高,显著优于常规对症治疗,值得临床推广应用。更多还原

【Abstract】 Objective To explore the efficacy and safety of escitalopram in the treatment of female involutional depression（ID）.Methods Forty-five female ID patients were assigned to two groups according to visiting sequence,research group（n= 22） took orally escitalopram and control group（n = 23） received routine symptomatic treatment for 8 weeks.Depressive symptoms were assessed with the Hamilton Depression Scale（HAMD） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before and after treatment.Results After treatment the HAMD scores of both groups lowered continuously,so did those at all time-points of treatment in research than in control group（P<0.05）;at the end of the 8^th week total effective rates were respectively 68.2%in research and 34.8%in control group,the former was significantly higher than the latter（x².14,P<0.01）.Adverse reactions of both groups were mild,there were no significant group differences in the incidences of adverse reactions（P>0.05）.Conclusion Escitalopram takes effect more rapidly,has an evident effect and higher safety compared with routine symptomatic treatment for female ID,and deserves clinical generalization and application.更多还原